The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
BIOE · Healthcare · Narrow moat
On the watchlist
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
CBLL · Healthcare · Narrow moat
On the watchlist
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
| Measure | IMAX | CDRE | BIOE | CBLL |
|---|---|---|---|---|
| Moat Score (0–100) | 61 (highest) | 61 (highest) | 61 (highest) | 61 (highest) |
| Methodology version | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 |
| Business trend | 80 | 89 (highest) | 65 | 70 |
| Pricing power | 66 | 68 | 57 | 100 (highest) |
| Returns on capital | 35 | 52 (highest) | — | — |
| Balance-sheet safety | 51 | 71 | 99 (highest) | 28 |
| Capital allocation | 74 (highest) | 28 | 24 | 47 |
| 167% above value if growth stopped today | 150% above value if growth stopped today (largest discount to value if growth stopped today) | No price data | No price data | |
| Market cap | $2.3B | $1.3B | $10.3M | $634M |
| Moat tier | Narrow moat | Narrow moat | Narrow moat | Narrow moat |
| Filing date | FY2025 | FY2025 | FY2025 | FY2025 |